Niche pain therapy Target pain management specialists and oncology clinics that treat high-intensity neuropathic and oncologic pain to explore CPR-T adoption as a non-invasive, non-narcotic option for resistant cases.

Clinical differentiation Position CPR-T as a biophysical treatment that complements or replaces conventional electro-analgesia for patients unresponsive to opioids, potentially expanding referrals from pain, palliative, and integrative medicine practices.

Strategic partnerships Leverage connections with Delta R&D and Professor Giuseppe Marineo’s network to credential the technology, while pursuing collaborations with academic medical centers to co-host trials and build credibility.

SMB market fit With a small team and revenue between one and ten million, target mid-size clinics and regional health systems seeking innovative, low-drug, non-invasive pain solutions to differentiate their service line.

Technology evangelism Develop targeted materials that explain CPR-T’s mechanism and clinical indications to IT-enabled health systems, highlighting potential for integration into existing electromedical device ecosystems and revenue opportunities.